Chiron Corporation has announced that the European Patent Office Technical Board of Appeals upheld the validity of Chiron’s European HCV Patent No. 0 318 216 in amended form. The final ‘216 patent contains broad claims that cover nucleic acid testing (NAT) for hepatitis C virus (HCV) detection and the manufacture, use or sale of such Read more about Chiron Patent For HCV Nucleic Acid Testing Upheld[…]
The post Chiron Patent For HCV Nucleic Acid Testing Upheld appeared first on Dragon Pharma Steroids.
